Izvorni znanstveni članak

METABOLIC SYNDROME IN SCHIZOPHRENIA - WHO IS MORE TO BLAME: FGA POLYPHARMACY OR CLOZAPINE MONOTHERAPY?

Rusmir Softic orcid.org/0000-0002-7420-1134 ; Department of Psychiatry, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina; School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Alija Sutovic ; Department of Psychiatry, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina; School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Esmina Avdibegovic ; Department of Psychiatry, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina; School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Enes Osmanović ; Heart Centre, Tuzla, Bosnia and Herzegovina
Elvir Bećirović ; Department of Psychiatry, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina; School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina
Mitra Mirković Hajdukov ; Department of Psychiatry, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina

Sažetak

Background: To establish the prevalence of metabolic syndrome and its parameters in group of patients with schizophrenia in
polypharmacy – receiving first generation antipsychotics versus clozapine alone treated group.
Subjects and methods: 48 outpatients with schizophrenia divided into two groups: the first group of 21 patients in polypharmacy
with first generation antipsychotics, and the second group of 27 patients treated with clozapine alone were assessed for the presence
of metabolic syndrome. We used logistic regression models to assess the relationship between metabolic syndrome and antipsychotic
therapy, gender and age.
Results: Metabolic syndrome was found in 52.1% of all subjects. Compared to first generation antipsychotics polypharmacy, the
monopharmacy with clozapine was associated with elevated rates of metabolic syndrome (28.6% vs. 70.4%, p=0.004). With regard
to particular parameters of metabolic syndrome, the elevated plasma triglycerides were significantly more present in subjects within
Clozapine group (p=0.03). Logistic regression analysis showed that female gender (p=0.004), and clozapine treatment (p=0.005)
were significantly associated with metabolic syndrome.
Conclusion: Compared to polypharmacy with first generation antipsychotics, the higher prevalence of metabolic syndrome is
found in patients treated with Clozapine alone. The most prevalent metabolic disorder is dyslipidemia.

Ključne riječi

schizophrenia - metabolic syndrome – polypharmacy - clozapine

Hrčak ID:

162540

URI

https://hrcak.srce.hr/162540

Datum izdavanja:

15.12.2015.

Posjeta: 823 *